Pear Therapeutics, a startup developing app-based therapy and tracking tools to help treat patients, raises $80M Series D led by SoftBank's Vision Fund 2
Context & Ripple Effects
SoftBank Vision Fund 2 is putting lead money behind app-based medicine: its $75M Series C for Big Health's Sleepio and Daylight CBT apps came fourteen months after this $80M Series D for Pear Therapeutics, making digital therapeutics a repeat theme for the fund rather than a one-off bet.
The round landed as the category was heating up on both sides of the software stack — BrightInsight raised $101M to build patient and doctor apps for drug and device makers, while Hinge Health's $400M raise at a $6.2B valuation showed investors paying up sharply for sensor-plus-app clinical services within months.
First-order effects
- Pear Therapeutics gains an $80M war chest from Vision Fund 2 to scale its FDA-regulated therapy and tracking apps at exactly the moment rival digital-health developers are raising nine-figure rounds.
- SoftBank adds a second anchor position in app-delivered behavioral care, pairing Pear's prescription-style tools with Big Health's consumer sleep and anxiety apps.
Second-order effects
- Competing app-based therapy developers now face a fund-backed peer with SoftBank-scale capital, pushing the likes of Big Health and Hinge Health toward larger, faster rounds to keep pace.
- Platform suppliers such as BrightInsight benefit as pharma and device makers see validated demand for regulated patient-facing software, widening the vendor market around the apps themselves.
Third-order effects
- If funding keeps flowing, digital therapeutics consolidates into a distinct industry layer between pharma and consumer wellness, with the eventual battleground being insurance reimbursement — the territory Grow Therapy later attacked by connecting patients with insurance-covered therapists.
- Vision Fund 2's repeated lead roles suggest mega-funds, not strategic healthcare investors, are setting the valuation pace for clinical software, raising the bar for any startup seeking a Series C or D in the category.
The trend: SoftBank Vision Fund 2 is treating app-based clinical care as a core thesis, repeatedly leading large rounds across digital therapeutics from 2020 onward.